Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.

ABSTRACT: Accumulation of mutant p53 proteins is frequently found in a wide range of cancers. While conventional antibodies fail to target intracellular proteins, proteosomal degradation results in the presentation of p53-derived peptides on the tumour cell surface by class I molecules of the major histocompatibility complex (MHC). Elevated levels of such p53-derived peptide-MHCs on tumour cells potentially differentiate them from healthy tissues. Here, we report the engineering of an affinity-matured human antibody, P1C1TM, specific for the unmutated p53_125-134 peptide in complex with the HLA-A24 class I MHC molecule. We show that P1C1TM distinguishes between mutant and wild-type p53 expressing HLA-A24⁺ cells, and mediates antibody dependent cellular cytotoxicity of mutant p53

SUBMITTER: Low L 

PROVIDER: S-EPMC6879612 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature